Spots Global Cancer Trial Database for chronic phase
Every month we try and update this database with for chronic phase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey | NCT03647215 | Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Ch... | 18 Years - | Incyte Corporation | ||
| Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan | NCT01464411 | Leukemia, Myelo... Myelogenous Leu... | 20 Months - | Kanto CML Study Group | ||
| A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | NCT01077544 | Chronic Myeloid... Acute Lymphobla... | Nilotinib | 1 Year - 17 Years | Novartis | |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | NCT02398825 | Chronic Myeloid... Chronic Phase Adults | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | NCT01570868 | Leukemia | Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | NCT02398825 | Chronic Myeloid... Chronic Phase Adults | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant | NCT00413270 | Chronic Myeloge... | nilotinib | 18 Years - | Novartis | |
| Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase | NCT00905593 | Chronic Myeloid... | Nilotinib | 18 Years - 60 Years | Novartis | |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | NCT04795427 | Leukemia, Chron... | asciminib best available ... | 18 Years - | Novartis | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) | NCT00760877 | CHRONIC MYELOGE... | Nilotinib Imatinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | NCT01570868 | Leukemia | Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. | NCT01844765 | Philadelphia Po... | nilotinib | 1 Year - 17 Years | Novartis | |
| Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | NCT00114959 | Myeloid Leukemi... Myeloid Leukemi... Blast Phase Myeloid Leukemi... | Homoharringtoni... Imatinib Mesyla... | 16 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib | NCT00644878 | Chronic Myeloge... | Nilotinib | 18 Years - | Novartis | |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | NCT04260022 | Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso... | Ascentage Pharm... Blinatumomab | 18 Years - | Ascentage Pharma Group Inc. | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | NCT01077544 | Chronic Myeloid... Acute Lymphobla... | Nilotinib | 1 Year - 17 Years | Novartis | |
| European Stop Tyrosine Kinase Inhibitor Study | NCT01596114 | Chronic Myeloid... | Stopping treatm... | 18 Years - | European LeukemiaNet | |
| An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment | NCT00980018 | Chronic Myeloge... | Nilotinib | 18 Years - | Novartis | |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | NCT01570868 | Leukemia | Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| European Stop Tyrosine Kinase Inhibitor Study | NCT01596114 | Chronic Myeloid... | Stopping treatm... | 18 Years - | European LeukemiaNet | |
| Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan | NCT01464411 | Leukemia, Myelo... Myelogenous Leu... | 20 Months - | Kanto CML Study Group | ||
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | NCT02398825 | Chronic Myeloid... Chronic Phase Adults | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | NCT04260022 | Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso... | Ascentage Pharm... Blinatumomab | 18 Years - | Ascentage Pharma Group Inc. | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors | NCT03481868 | Chronic Myeloid... Chronic Phase | Collection of b... | 18 Years - | University Hospital, Clermont-Ferrand |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
